These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1884741)

  • 41. Profile of non-compliance in lymphoblastic leukaemia.
    Lancaster D; Lennard L; Lilleyman JS
    Arch Dis Child; 1997 Apr; 76(4):365-6. PubMed ID: 9166035
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study.
    Lowe ES; Kitchen BJ; Erdmann G; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Woods W; Franklin J; Widemann BC; Balis FM; Murphy RF; Adamson PC
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):199-205. PubMed ID: 11320662
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations.
    Lennard L; Keen D; Lilleyman JS
    Clin Pharmacol Ther; 1986 Sep; 40(3):287-92. PubMed ID: 3461899
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 'Acceptability' of a new oral suspension formulation of mercaptopurine in children with acute lymphoblastic leukaemia.
    Mulla H; Buck H; Price L; Parry A; Bell G; Skinner R
    J Oncol Pharm Pract; 2016 Jun; 22(3):387-95. PubMed ID: 25837624
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Importance of oral antimetabolite "maintenance" therapy in childhood lymphoblastic leukemia.
    Lilleyman JS
    Pediatr Hematol Oncol; 1996; 13(5):vii-x. PubMed ID: 10897808
    [No Abstract]   [Full Text] [Related]  

  • 46. Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia.
    Zou Y; Mei D; Yuan J; Han J; Xu J; Sun N; He H; Yang C; Zhao L
    Int J Nanomedicine; 2021; 16():1127-1141. PubMed ID: 33603372
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia.
    Innocenti F; Danesi R; Favre C; Nardi M; Menconi MC; Di Paolo A; Bocci G; Fogli S; Barbara C; Barachini S; Casazza G; Macchia P; Del Tacca M
    Ther Drug Monit; 2000 Aug; 22(4):375-82. PubMed ID: 10942174
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Why more 6-mercaptopurine?
    Kamen BA
    Semin Hematol; 1991 Jul; 28(3 Suppl 4):12-4. PubMed ID: 1780746
    [No Abstract]   [Full Text] [Related]  

  • 49. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
    Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
    Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia.
    Sulh H; Koren G; Whalen C; Soldin S; Zipursky A; Greenberg M
    Clin Pharmacol Ther; 1986 Dec; 40(6):604-9. PubMed ID: 3465489
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy?
    Balis FM; Jeffries SL; Lange B; Murphy RF; Doherty KM; Arndt CA; Luery N; Poplack DG
    Am J Pediatr Hematol Oncol; 1989; 11(3):324-6. PubMed ID: 2782561
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia.
    Lennard L; Hale JP; Lilleyman JS
    Br J Clin Pharmacol; 1993 Oct; 36(4):277-84. PubMed ID: 12959304
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia.
    Tanaka Y; Manabe A; Fukushima H; Suzuki R; Nakadate H; Kondoh K; Nakamura K; Koh K; Fukushima T; Tsuchida M; Koike K; Kiyokawa N; Noguchi E; Sumazaki R; Komiyama T
    Pharmacogenomics J; 2015 Aug; 15(4):380-4. PubMed ID: 25403995
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.
    Petersen KB; Jusko WJ; Rasmussen M; Schmiegelow K
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):465-73. PubMed ID: 12698270
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia.
    Adamson PC; Zimm S; Ragab AH; Balis F; Steinberg SM; Kamen BA; Vietti TJ; Gillespie A; Poplack DG
    Cancer Chemother Pharmacol; 1992; 30(2):155-7. PubMed ID: 1600597
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Individualized 6-mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia: A NOPHO randomized controlled trial.
    Tulstrup M; Frandsen TL; Abrahamsson J; Lund B; Vettenranta K; Jonsson OG; Marquart HVH; Albertsen BK; Heyman M; Schmiegelow K
    Eur J Haematol; 2018 Jan; 100(1):53-60. PubMed ID: 28983968
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-performance liquid chromatographic assay of methylthioguanine nucleotide.
    Rowland K; Lennard L; Lilleyman JS
    J Chromatogr B Biomed Sci Appl; 1998 Jan; 705(1):29-37. PubMed ID: 9498667
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of two 6-mercaptopurine liquid formulations in children with acute lymphoblastic leukemia.
    Tolbert JA; Bai S; Abdel-Rahman SM; August KJ; Weir SJ; Kearns GL; Neville KA
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28295989
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance?
    Davies HA; Lennard L; Lilleyman JS
    BMJ; 1993 May; 306(6887):1239-40. PubMed ID: 8499854
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of a Daily Text Messaging and Directly Supervised Therapy Intervention on Oral Mercaptopurine Adherence in Children With Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Bhatia S; Hageman L; Chen Y; Wong FL; McQuaid EL; Duncan C; Mascarenhas L; Freyer D; Mba N; Aristizabal P; Walterhouse D; Lew G; Kempert PH; Russell TB; McNall-Knapp RY; Jacobs S; Dang H; Raetz E; Relling MV; Landier W
    JAMA Netw Open; 2020 Aug; 3(8):e2014205. PubMed ID: 32852553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.